Inozyme Pharma Stock News

BOSTON, June 01, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal miner

Inozyme Pharma Inc (NASDAQ: INZY) has dosed the first patient in its Phase 1/2 trial of INZ-701 in adult patients with ABCC6 Deficiency. Also, the second cohort in the ongoing Phase 1/2 clinical tr

BOSTON, April 06, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, t

Inozyme Pharma Inc (NASDAQ: INZY) announced preliminary biomarker, safety, and pharmacokinetic (PK) data from the first three patients treated in the Phase 1 portion of its Phase 1/2 trial of INZ-7

Inozyme Pharma press release (INZY): FY GAAP EPS of -$2.40 misses by $0.11.Cash, cash equivalents, and investments were $111.8 million as of December 31, 2021.

– Phase 1/2 trial of INZ-701 in adult patients with ENPP1 Deficiency underway –

Inozyme Pharma (INZY) has announced two executive appointments, with Sanjay Subramanian joining the team as CFO and Soojin Kim as SVP and Chief Technical Operations Officer ((CTOO)). Mr

BOSTON, March 08, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mi

BOSTON, March 01, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization,

BOSTON, March 01, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced Axel Bolte, MSc, MBA, the company’s co-founder, president, and chief executive officer, will participate in a fireside chat at the Cowen 42 nd Annual Health Care Conference on Tuesday, March 8 th at 11:10 AM ET.

BOSTON, March 01, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, t

H.C. Wainwright had initiated Inozyme Pharma with a buy based on optimism for its enzyme replacement therapy INZ-701.

Upgrades For Enova International Inc (NYSE:ENVA), Maxim Group upgraded the previous rating of Hold to Buy. For the fourth quarter, Enova International had an EPS of $1.61, compared to year-ago quarter

Inozyme Pharma Inc (INZY) shares closed today 10.3% higher than it did at the end of yesterday. The stock is currently up 0.4% year-to-date, down 73.6% over the past 12 months, and down 60.9% over the past five years. Today, the Dow Jones Industrial Average rose 0.5%, and the S&P 500 rose 0.9%. Trading Activity Shares traded as high as $7.04 and as low as $6.00 this week.Shares closed 76.7% below its 52-week high and 28.5% above its 52-week low.Trading volume this week was 59.4% lower than the 10-day average and 78.6% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.3. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price beats the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector today, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -130.5% The company's stock price performance over the past 12 months lags the peer average by 341.1% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Needham & Company LLC initiated coverage on shares of Inozyme Pharma (NASDAQ:INZY) in a research report report published on Monday, Analyst Ratings Network reports. The firm issued a buy rating and a $23.00 target price on the stock. Separately, Zacks Investment Research lowered shares of Inozyme Pharma from a buy rating to a hold rating []